The incidence of grade @ or more adverse events ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) and serious adverse events ( @ -LSB- @ % -RSB- vs five -LSB- @ % -RSB- ) was similar in each group despite longer median treatment duration with siltuximab than with placebo ( @ days -LSB- range @-@ -RSB- vs @ days -LSB- @-@ -RSB- ) .